keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemotherapy in breast cancer

keyword
https://www.readbyqxmd.com/read/29915946/impact-of-change-in-body-mass-index-during-neoadjuvant-chemotherapy-and-survival-among-breast-cancer-subtypes
#1
Takahiro Kogawa, Takeo Fujii, Tamer M Fouad, Diane D Liu, Kenichi Harano, Hiroko Masuda, Toshiaki Iwase, Chad Barnett, Young Sam Park, Bora Lim, Debu Tripathy, Jennifer K Litton, Naoto T Ueno
PURPOSE: We hypothesized that an increase in BMI category during neoadjuvant chemotherapy (NAC) would be associated with pathological complete response (pCR) rate and worse survival outcomes in primary breast cancer patients. METHODS: We reviewed the records of 4029 patients with stage I-III breast cancer who had undergone NAC and definitive surgery at our institution between May 1, 1990 and April 30, 2013. BMI values at baseline and after NAC were recorded, and the corresponding BMI category was assessed with the WHO classification...
June 18, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29915436/assessment-of-tumor-response-to-neoadjuvant-chemotherapy-in-patients-with-breast-cancer-using-mri-and-fdg-pet-ct-recist-1-1-vs-percist-1-0
#2
Kazuhiro Kitajima, Yasuo Miyoshi, Toshiko Yamano, Soichi Odawara, Tomoko Higuchi, Koichiro Yamakado
Therapeutic response to neoadjuvant chemotherapy (NAC) for breast cancer based on Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 with FDG-PET/CT measurements was evaluated, and the results compared to those obtained with currently widely used Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, based on MRI measurements. MRI and FDG-PET/CT examinations were performed in 32 breast cancer patients before and after the NAC prior to a surgical resection. Chemotherapeutic response of the primary tumor and relapse-free survival (RFS) were investigated using RECIST 1...
May 2018: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/29910658/clinical-practice-guidelines-in-breast-cancer
#3
REVIEW
N Kumar Tyagi, S Dhesy-Thind
Background: A number of clinical practice guidelines (cpgs) concerning breast cancer (bca) screening and management are available. Here, we review the strengths and weaknesses of cpgs from various professional organizations and consensus groups with respect to their methodologic quality, recommendations, and implementability. Methods: Guidelines from four groups were reviewed with respect to two clinical scenarios: adjuvant ovarian function suppression (ofs) in premenopausal women with early-stage estrogen receptor-positive bca, and use of sentinel lymph node biopsy (slnb) after neoadjuvant chemotherapy (nac) for locally advanced bca...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910657/advances-in-the-systemic-treatment-of-triple-negative-breast-cancer
#4
REVIEW
J M Lebert, R Lester, E Powell, M Seal, J McCarthy
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29908524/neoadjuvant-radiotherapy-changing-the-treatment-sequence-to-allow-immediate-free-autologous-breast-reconstruction
#5
Kimberley Hughes, Derek Neoh
BACKGROUND:  Locally advanced breast cancer (LABC) is traditionally treated with a multimodal approach of chemotherapy, surgery, and postmastectomy radiotherapy (PMRT). The advantages of immediate breast reconstruction (IBR) are well described and include improved aesthetic outcomes, fewer surgical procedures, shorter treatment period, and a higher quality of life. However, this sequence makes immediate free autologous reconstruction more challenging as PMRT can have deleterious and unpredictable effects on the flap...
June 16, 2018: Journal of Reconstructive Microsurgery
https://www.readbyqxmd.com/read/29905606/the-effect-of-the-histone-deacetylase-inhibitor-suberoylanilide-hydroxamic-acid-and-paclitaxel-treatment-on-full-thickness-wound-healing-in-mice
#6
Joseph H Marcotte, Deviney A Rattigan, Robin F Irons, Kevin W Cahill, Ping Zhang, Shaohua Chang, Kiavash R Koko, John P Gaughan, Jeffrey P Carpenter, Spencer A Brown, Tulin Budak-Alpdogan
INTRODUCTION: Neoadjuvant chemotherapy prior to lumpectomy or mastectomy for breast cancer challenges wound healing. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, has been shown to work synergistically with paclitaxel in vitro and in preclinical studies. In addition, our laboratory has demonstrated that SAHA treatment decreases paclitaxel-associated stem cell toxicity, modulates inflammatory response, and promotes wound healing in injured fibroblast cells. Our goal was to determine if combined SAHA and paclitaxel treatment would improve wound healing in an in vivo full-thickness murine model, without altering antitumor effect...
June 13, 2018: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/29905023/neoadjuvant-endocrine-therapy-with-exemestane-followed-by-response-guided-combination-therapy-with-low-dose-cyclophosphamide-in-postmenopausal-patients-with-estrogen-receptor-positive-breast-cancer-a-multicenter-open-label-phase-ii-study
#7
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Patients with estrogen receptor (ER)-positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone-sensitive patients. Most patients with ER-positive breast cancer are postmenopausal, and therefore, generally older and less able to tolerate chemotherapy. We aimed to investigate the efficacy and safety of tailored neoadjuvant endocrine and chemoendocrine therapy for postmenopausal breast cancer patients...
June 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29899867/triple-negative-breast-cancer-subtypes-and-pathologic-complete-response-rate-to-neoadjuvant-chemotherapy
#8
Angela Santonja, Alfonso Sánchez-Muñoz, Ana Lluch, Maria Rosario Chica-Parrado, Joan Albanell, José Ignacio Chacón, Silvia Antolín, José Manuel Jerez, Juan de la Haba, Vanessa de Luque, Cristina Elisabeth Fernández-De Sousa, Luis Vicioso, Yéssica Plata, César Luis Ramírez-Tortosa, Martina Álvarez, Casilda Llácer, Irene Zarcos-Pedrinaci, Eva Carrasco, Rosalía Caballero, Miguel Martín, Emilio Alba
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin...
May 29, 2018: Oncotarget
https://www.readbyqxmd.com/read/29898762/identifying-an-early-treatment-window-for-predicting-breast-cancer-response-to-neoadjuvant-chemotherapy-using-immunohistopathology-and-hemoglobin-parameters
#9
Quing Zhu, Susan Tannenbaum, Scott H Kurtzman, Patricia DeFusco, Andrew Ricci, Hamed Vavadi, Feifei Zhou, Chen Xu, Alex Merkulov, Poornima Hegde, Mark Kane, Liqun Wang, Kert Sabbath
BACKGROUND: Breast cancer pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) varies with tumor subtype. The purpose of this study was to identify an early treatment window for predicting pCR based on tumor subtype, pretreatment total hemoglobin (tHb) level, and early changes in tHb following NAC. METHODS: Twenty-two patients (mean age 56 years, range 34-74 years) were assessed using a near-infrared imager coupled with an Ultrasound system prior to treatment, 7 days after the first treatment, at the end of each of the first three cycles, and before their definitive surgery...
June 14, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29898745/amide-chemical-exchange-saturation-transfer-at-7-t-a-possible-biomarker-for-detecting-early-response-to-neoadjuvant-chemotherapy-in-breast-cancer-patients
#10
Erwin Krikken, Vitaliy Khlebnikov, Moritz Zaiss, Rajni A Jibodh, Paul J van Diest, Peter R Luijten, Dennis W J Klomp, Hanneke W M van Laarhoven, Jannie P Wijnen
BACKGROUND: The purpose of this work was to investigate noninvasive early detection of treatment response of breast cancer patients to neoadjuvant chemotherapy (NAC) using chemical exchange saturation transfer (CEST) measurements sensitive to amide proton transfer (APT) at 7 T. METHODS: CEST images were acquired in 10 tumors of nine breast cancer patients treated with NAC. APT signals in the tumor, before and after the first cycle of NAC, were quantified using a three-pool Lorentzian fit of the z-spectra in the region of interest...
June 14, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29895124/smac-protein-expression-as-a-potent-favorable-prognostic-factor-in-locally-advanced-breast-cancer
#11
Piotr Pluta, Dorota Jesionek-Kupnicka, Joanna Kubicka-Wołkowska, Agnieszka Pluta, Kamil Brzozowski, Piotr Potemski, Janusz Piekarski, Radzisław Kordek, Arkadiusz Jeziorski
Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC. The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB -node positive and III), who received NCT followed by surgery and adjuvant treatment...
2018: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/29893791/trastuzumab-versus-observation-for-her2-non-amplified-early-breast-cancer-with-circulating-tumor-cells-eortc-90091-10093-big-1-12-treat-ctc-a-randomized-phase-2-trial
#12
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29893329/the-importance-of-stromal-and-intratumoral-tumor-lymphocyte-infiltration-for-pathologic-complete-response-in-patients-with-locally-advanced-breast-cancer
#13
Melek Karakurt Eryilmaz, Hasan Mutlu, Betül Ünal, Derya Kıvrak Salim, Fatma Yalçın Musri, Hasan Şenol Coşkun
Objective: Increased tumor-infiltrating lymphocytes (TILs) in breast carcinoma tissues is an independent predictive factor for pathologic complete response (pCR). The increased intratumoral and stromal TILs (sTILs) in breast cancer (BC) have significant prognostic effects. In this study, we evaluated whether pCR rates to neoadjuvant chemotherapy (NACT) are higher in tumors with increased number of TILs in the pretreatment biopsy. Materials and Methods: We retrospectively evaluated the number of TILs in intratumoral TILs (iTILs) and sTILs compartments from pretreatment full-face hematoxylin and eosin-stained sections of 62 patients with locally advanced BC (LABC) who received NACT...
April 2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29887788/using-a-new-marker-clip-system-in-breast-cancer-tumark-vision%C3%A2-clip-feasibility-testing-in-everyday-clinical-practice
#14
Anna Marlene Rüland, Friederike Hagemann, Mattea Reinisch, Johannes Holtschmidt, Aylin Kümmel, Christine Dittmer-Grabowski, Frank Stöblen, Horst Rotthaus, Volker Dreesmann, Jens-Uwe Blohmer, Sherko Kümmel
Background: This study presents first feasibility experiences with a new 3-dimensional (3D) marker clip system in clinical practice. The rate of clinical complete responses in the treatment of breast cancer patients is increasing; additionally, a change to targeted axillary dissection is being considered after neoadjuvant chemotherapy (NACT). Consequently, marker clips are needed which are reliable and easy to handle even in the axillary lymph node system. Methods: A total of 50 patients from the Breast Care Unit of the Kliniken Essen Mitte were included...
April 2018: Breast Care
https://www.readbyqxmd.com/read/29883779/tumor-infiltrating-lymphocyte-volume-is-a-better-predictor-of-neoadjuvant-therapy-response-and-overall-survival-in-triple-negative-invasive-breast-cancer
#15
Lin Zhang, Xiaohong I Wang, Songlin Zhang
Triple-negative breast cancer (TNBC) has an aggressive behavior, limited therapeutic options, and high mortality rate. Neoadjuvant chemotherapy (NACT) is a standard treatment for TNBC and patients with pathological complete response (pCR) have a favorable outcome. We conducted a comprehensive evaluation of cancer clinicopathologic parameters, and correlated these parameters with the pCR rate and the overall survival. Fifty-eight patients with TNBC of no special type who underwent breast biopsy, neoadjuvant therapy, and mastectomy in our institution during 2005-2016 were included in this study...
June 5, 2018: Human Pathology
https://www.readbyqxmd.com/read/29880292/efficacy-and-safety-of-abp-980-compared-with-reference-trastuzumab-in-women-with-her2-positive-early-breast-cancer-lilac-study-a-randomised-double-blind-phase-3-trial
#16
Gunter von Minckwitz, Marco Colleoni, Hans-Christian Kolberg, Serafin Morales, Patricia Santi, Zorica Tomasevic, Nan Zhang, Vladimir Hanes
BACKGROUND: ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and pharmacokinetic similarities. We compared the clinical safety and efficacy of ABP 980 with that of trastuzumab in women with HER2-positive early breast cancer. METHODS: We did a randomised, multicentre, double-blind, active-controlled equivalence trial at 97 study centres in 20 countries, mainly in Europe and South America. Eligible women were aged 18 years or older, had histologically confirmed HER2-positive invasive early breast cancer, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and were planning to have surgical resection of the breast tumour with sentinel or axillary lymph node dissection and neoadjuvant chemotherapy...
June 4, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29879283/safety-and-efficacy-of-panitumumab-plus-neoadjuvant-chemotherapy-in-patients-with-primary-her2-negative-inflammatory-breast-cancer
#17
Naoko Matsuda, Xiaoping Wang, Bora Lim, Savitri Krishnamurthy, Ricardo H Alvarez, Jie S Willey, Charla A Parker, Juhee Song, Yu Shen, Jianhua Hu, Wenhui Wu, Nan Li, Gildy V Babiera, James L Murray, Banu K Arun, Abenaa M Brewster, James M Reuben, Michael C Stauder, Chad M Barnett, Wendy A Woodward, H T Carisa Le-Petross, Anthony Lucci, Sarah M DeSnyder, Debu Tripathy, Vicente Valero, Naoto T Ueno
Importance: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in patients with IBC. Objective: To evaluate the safety and efficacy of the anti-EGFR antibody panitumumab plus neoadjuvant chemotherapy in patients with primary human epidermal growth factor receptor 2 (HER2)-negative IBC...
June 7, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29877880/hematopoietically-active-adrenal-myelolipoma-mimicking-breast-cancer-metastasis
#18
John J Manov, Alexander Diaz-Bode, Russ Kuker
A 66-year old woman had a left breast mass. Biopsy showed invasive ductal carcinoma. A PET/CT scan demonstrated hypermetabolism in the left breast and atypical heterogeneously increased uptake throughout the skeleton as well as a minimally FDG-avid right adrenal myelolipoma. PET/CT 4 months later after 6 cycles of neoadjuvant chemotherapy demonstrated increased size and FDG avidity of this adrenal mass concerning for metastasis and uniformly increased skeletal FDG avidity. Biopsy demonstrated adrenal myelolipoma...
June 5, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29875927/descriptive-study-of-triple-negative-breast-cancer-in-eastern-algeria
#19
Haddad Souad, Frimeche Zahia, Lakehal Abdelhak, Sifi Karima, Satta Dalila, Abadi Noureddine
Introduction: Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (HER-2) expression. It is aggressive and most common in African women. In this study we identified the frequency, clinical an pathological characteristics of this type in a cohort of women in Eastern Algeria. Methods: We conducted a retrospective study between January 2010 and December 2015 at the regional hospital of Constantine in eastern Algeria...
2018: Pan African Medical Journal
https://www.readbyqxmd.com/read/29873695/platinum-based-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-systematic-review-and-meta-analysis
#20
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini
Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients...
June 4, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
55442
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"